Curaleaf maintains Aurora bid after rival Organigram proposal
- Curaleaf's enhanced Oct. 6, 2026, offer for all outstanding Aurora Cannabis common shares remains outstanding despite Organigram Global's alternative proposal.
- The bidder maintains its offer provides better value, greater closing certainty and higher anticipated synergies.
- It criticized Aurora's board for granting Organigram due diligence access while denying it access, arguing this blocks a potentially enhanced bid.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curaleaf Holdings Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202611031744CANADANWCANADAPR_C4469) on November 03, 2026, and is solely responsible for the information contained therein.